more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

US$12 Billion RNA Deal Triggers Sector Shakeup

  ()
Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026.
Tags: Biotechnology / Pharmaceuticals

Lead Drug Faces Uncertain FDA Path After Phase 3 Miss

  ()
aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward.
Tags: Biotechnology / Pharmaceuticals

Preclinical Compounds Perform Better Than Existing Drugs

Research Report
  ()
Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials

  ()
Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management.
Tags: Biotechnology / Pharmaceuticals

Biotech to Fast Track Phase 3 Depression Trial

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report.
Tags: Biotechnology / Pharmaceuticals

Co. Speeds Up Development of New Drug for Depression

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report.
Tags: Biotechnology / Pharmaceuticals

2 Key Catalysts Ahead for Developer of Psych Drugs

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Price Target on Psychiatric Drug Biotech Boosted 200%

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

US Biopharma In-Licenses 3 New Assets

Research Report
  ()
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

Chen's High-Grade Gold, Silver Plays for Q4

  ()
It has been quite a year for precious metals such as gold and silver, and Chen Lin's top stock picks for the quarter bear that out. Which companies have the most upside?
Tags: CopperBiotechnology / PharmaceuticalsGoldSilver

AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is set to unveil new preclinical data from its AI-driven ATR inhibitor program at a major international cancer conference in Boston. The findings highlight strong efficacy and blood-brain barrier permeability, a potential breakthrough for hard-to-treat tumors and brain metastases.
Tags: Healthcare ServicesBiotechnology / Pharmaceuticals

Biopharma's New MASH Drug Has Two MOAs

Research Report
  ()
Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Pharma Announces Faster Approval Pathway for Neurodegenerative Disease

Research Report
  ()
Lexeo Therapeutics Inc. (LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases.
Tags: Biotechnology / PharmaceuticalsRegenerative Medicine

Therapeutics Company Advances Gene Therapy Breakthrough

Research Report
  ()
In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. (LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval.
Tags: Regenerative MedicineBiotechnology / Pharmaceuticals

New Drug for Duchenne Muscular Dystrophy Nears Potential Approval

Research Report
  ()
Capricor Therapeutics Inc. (CAPR:NASDAQ) could receive a PDUFA date for its cell therapy as early as spring 2026 if it follows the FDA-outlined path forward, noted an Alliance Global Partners report.
Tags: Biotechnology / Pharmaceuticals

Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy

  ()
Capricor Therapeutics Inc. (CAPR:NASDAQ) reached agreement with the FDA to include HOPE-3 trial data in its BLA for Deramiocel, its cell therapy for Duchenne muscular dystrophy. With topline results due in Q4, learn how the company is advancing one of the few late-stage programs in this high-need rare disease space.
Tags: Biotechnology / Pharmaceuticals

Pharma's Flu Drug Could Be Worth Billions, Analyst Says

Research Report
  ()
Cidara Therapeutics Inc. (CDTX:NASDAQ) shares the minutes from an important meeting with the FDA, and the overall feedback was encouraging. Find out what one analyst predicts that will mean for Phase III development.
Tags: Biotechnology / Pharmaceuticals

Biotech Discovers Breakthrough DMD Therapy Opportunity

Research Report
  ()
Capricor Therapeutics Inc. (CAPR:NASDAQ) recently announced a favorable regulatory update, according to a research note from Oppenheimer & Co Inc.
Tags: Biotechnology / Pharmaceuticals

Healthcare Firm Targets Alzheimer's With Technology Breakthrough

  ()
Healthcare company Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need.
Tags: Biotechnology / Pharmaceuticals

Seeking Formulation of New Drug, Biopharma Co. Signs LOI

Research Report
  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Biopharma Firm Accelerates AI-Driven Cancer Drug Discovery in Canada

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) secured fresh funding, advanced preclinical PARP and ATR programs, and leveraged exclusive AI platforms to target DNA-repair pathways. Read more for insight into its expanding role in precision oncology.
Tags: Biotechnology / Pharmaceuticals

Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial

  ()
Kyverna Therapeutics Inc. (KYTX:NASDAQ) unveiled the design of its U.S. registrational Phase 3 trial for KYV-101 in myasthenia gravis during a Key Opinion Leader event, following ≥ 15-month remission data in Germany. Read more to see what sets this trial apart.
Tags: Biotechnology / Pharmaceuticals

Biotech Announces Topline Results From Cardiovascular Drug Trial

Research Report
  ()
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) Analyst Brandon Folkes reviews Cardiol Therapeutics Inc. after it announced the topline results from its Phase II ARCHER trial of CardiolRx in acute myocarditis.
Tags: Biotechnology / Pharmaceuticals

Pharmaceutical Company Discovers Breakthrough Heart Treatment in Canada

Research Report
  ()
Top-line results from Cardiol Therapeutics' (CRDL:TSX; CRDL:NASDAQ) ARCHER study for Acute Myocarditis are quite promising, writes Roth Capital Partners Analyst Jason Wittes in an updated research note.
Tags: Biotechnology / Pharmaceuticals

Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment

  ()
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) announces topline results from its Phase II clinical study involving patients with acute myocarditis. Read why analysts like this pharmaceutical stock.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 57 Next